PepGen Ltd (PEPG)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at PepGen Ltd.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Analysts & Price Target
The price target sits 469.4% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.30 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.32 | – | 2 | -10.10 | -1,490.80 | -20 | -20 |
| 2025: Q1 | -0.44 | – | 0 | – | – | -23 | -23 |
| 2025: Q2 | -0.33 | – | 0 | – | – | -24 | -24 |
| 2025: Q3 | -0.26 | – | 0 | – | – | -19 | -19 |
| 2025: Q4 | -0.27 | – | 0 | -100.00 | – | -16 | -16 |
| 2026: Q1 | -0.26 | – | 0 | – | – | -18 | -18 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
PepGen Inc., ein Biotechnologieunternehmen in der klinischen Phase, entwickelt Oligonukleotid-Therapeutika zur Behandlung schwerer neuromuskulärer und neurologischer Erkrankungen in den USA.
| Employees | 59 |
|---|---|
| Headquarters | Boston, MA |
| Website | pepgen.com |
| IPO Date | 6. May 2022 |
Management
| Name | Title | Birth Year |
|---|---|---|
| James G. McArthur Ph.D. | President, CEO, Treasurer, Secretary & Director | 1962 |
| Noel P. Donnelly M.B.A. | Chief Financial Officer | 1970 |
| Joseph D. Vittiglio Esq., J.D. | Chief Business & Legal Officer and Secretary | 1972 |
| Kasra Kasraian Ph.D. | Chief Technical Officer | 1967 |
| Emiko Bryant | Senior Vice President of HR & Administration | – |
| Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs & Quality | – |
| Paul D. Streck M.B.A., M.D. | Executive VP and Head of Research & Development | 1964 |
| Pallavi Lonkar Ph.D. | Vice President & Head of Preclinical | – |
| Gregory Song | Executive Director & Head of Biometrics | – |
| Melissa Michaels | Executive Director & Head of Regulatory Affairs CMC | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.